Background/Aims: The study aim was to evaluate if mTOR inhibitors can be considered as a treatment option for HR+ HER2- metastatic breast cancer (MBC) after progression on CDK4/6 inhibitors in clinical practice. Methods: We retrospectively collected the clinicopathological data of patients with HR+ HER2- MBC treated with CDK4/6 inhibitors and subsequent therapies at our institution between 2014 and 2020. The patients were divided into 3 groups according to the type of subsequent treatment: (A) exemestane plus everolimus, (B) endocrine monotherapy, and (C) chemotherapy. Overall survival (OS) was estimated by using the Kaplan-Meier method and compared by using the log-rank test. The efficacy and adverse events (AEs) of each subsequent treatment were assessed by using Fisher's exact tests. Results: Eighty-six patients (34 in group A, 20 in group B, 32 in group C) were included. The most common endocrine therapy in group B was fulvestrant (40%). The major chemotherapy regimen in group C was eribulin (25%). The median OS times after stopping CDK4/6 inhibitors were 34.5 months (95% confidence interval, 17.2 to NA), 13.6 months (3.9 to NA), and 19.5 months (18.8 to NA) in group A, group B, and group C, respectively. The only significant difference in OS was observed between group A and group B (20.9 months; p = 0.003). There was no difference in the incidence of grade 3 AEs between groups A and C or in the frequency of treatment discontinuation because of AEs among the 3 groups. Conclusion: Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2- MBC previously treated with CDK4/6 inhibitors.
Background/Aims: The study aim was to evaluate if mTOR inhibitors can be considered as a treatment option for HR+ HER2- metastatic breast cancer (MBC) after progression on CDK4/6 inhibitors in clinical practice. Methods: We retrospectively collected the clinicopathological data of patients with HR+ HER2- MBC treated with CDK4/6 inhibitors and subsequent therapies at our institution between 2014 and 2020. The patients were divided into 3 groups according to the type of subsequent treatment: (A) exemestane plus everolimus, (B) endocrine monotherapy, and (C) chemotherapy. Overall survival (OS) was estimated by using the Kaplan-Meier method and compared by using the log-rank test. The efficacy and adverse events (AEs) of each subsequent treatment were assessed by using Fisher's exact tests. Results: Eighty-six patients (34 in group A, 20 in group B, 32 in group C) were included. The most common endocrine therapy in group B was fulvestrant (40%). The major chemotherapy regimen in group C was eribulin (25%). The median OS times after stopping CDK4/6 inhibitors were 34.5 months (95% confidence interval, 17.2 to NA), 13.6 months (3.9 to NA), and 19.5 months (18.8 to NA) in group A, group B, and group C, respectively. The only significant difference in OS was observed between group A and group B (20.9 months; p = 0.003). There was no difference in the incidence of grade 3 AEs between groups A and C or in the frequency of treatment discontinuation because of AEs among the 3 groups. Conclusion: Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2- MBC previously treated with CDK4/6 inhibitors.
Authors: M Piccart; G N Hortobagyi; M Campone; K I Pritchard; F Lebrun; Y Ito; S Noguchi; A Perez; H S Rugo; I Deleu; H A Burris; L Provencher; P Neven; M Gnant; M Shtivelband; C Wu; J Fan; W Feng; T Taran; J Baselga Journal: Ann Oncol Date: 2014-09-17 Impact factor: 32.976
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Matthew P Goetz; Masakazu Toi; Mario Campone; Joohyuk Sohn; Shani Paluch-Shimon; Jens Huober; In Hae Park; Olivier Trédan; Shin-Cheh Chen; Luis Manso; Orit C Freedman; Georgina Garnica Jaliffe; Tammy Forrester; Martin Frenzel; Susana Barriga; Ian C Smith; Nawel Bourayou; Angelo Di Leo Journal: J Clin Oncol Date: 2017-10-02 Impact factor: 44.544
Authors: Hope S Rugo; R Bryan Rumble; Erin Macrae; Debra L Barton; Hannah Klein Connolly; Maura N Dickler; Lesley Fallowfield; Barbara Fowble; James N Ingle; Mohammad Jahanzeb; Stephen R D Johnston; Larissa A Korde; James L Khatcheressian; Rita S Mehta; Hyman B Muss; Harold J Burstein Journal: J Clin Oncol Date: 2016-05-23 Impact factor: 44.544
Authors: F Cardoso; S Paluch-Shimon; E Senkus; G Curigliano; M S Aapro; F André; C H Barrios; J Bergh; G S Bhattacharyya; L Biganzoli; F Boyle; M-J Cardoso; L A Carey; J Cortés; N S El Saghir; M Elzayat; A Eniu; L Fallowfield; P A Francis; K Gelmon; J Gligorov; R Haidinger; N Harbeck; X Hu; B Kaufman; R Kaur; B E Kiely; S-B Kim; N U Lin; S A Mertz; S Neciosup; B V Offersen; S Ohno; O Pagani; A Prat; F Penault-Llorca; H S Rugo; G W Sledge; C Thomssen; D A Vorobiof; T Wiseman; B Xu; L Norton; A Costa; E P Winer Journal: Ann Oncol Date: 2020-09-23 Impact factor: 32.976